Tandem high-dose chemotherapy with topotecan –thiotepa–carboplatin and melphalan–etoposide–carboplatin regimens for pediatric high-risk brain tumors

ConclusionsAlthough tandem HDC/auto-SCT with TTC/MEC regimens showed promising survival rates, treatment modifications are warranted to reduce toxicities. The survival rates with relapsed brain tumors were unsatisfactory despite HDC/auto-SCT, and further study is needed.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research